HOME>News Release

News Release

  • Mitsubishi Tanabe Pharma
  • Former Mitsubishi Pharma
  • RSS
  • About RSS


July 16
As the First ALS Treatment in Indonesia RADICAVA has been approved first in ASEAN countriesPDF
July 15
Initiatives Against COVID-19 in Canada - Initiated Phase 1 Clinical Trials of VLP Vaccine CandidatePDF
July 8
Announcement of Collaboration between Medicago and GSK in the Development of COVID-19 Vaccine and the Start of Phase 1 Clinical TrialsPDF
June 29
Manufacturing and Marketing Approval of VAFSEO Tablets (HIF-PH inhibitor, vadadustat) for renal anemia in JapanPDF
June 26
Notification of Marketing Authorization Application for Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder in JapanPDF
June 15
Start of a Phase 3 Clinical Trial of MT-7117 for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)PDF
May 25
Regulatory Approval of Thailand for Marketing Teneligliptin (MP-513), a treatment agent for type 2 diabetes mellitusPDF
May 18
Initiatives Against COVID-19 in Canada -Intermediary Results of VLP Vaccine Pre-clinical StudyPDF
May 18
Co-marketing agreement concerning Vadadustat (MT-6548) for renal anemia in Japan with Fuso Pharmaceutical in hemodialysis and peritoneal dialysis patientsPDF
April 28
Notification of Changes in the U.S. Development Plan of VLP Vaccine for Seasonal Influenza Prevention (MT-2271) and an Impairment Loss (Non-recurring Items)PDF
April 1
SIMPONI self-injection formulation for ulcerative colitis now reimbursed through NHIPDF
March 25
STELARA (ustekinumab) Now Approved for the Treatment of Adults with Moderate-to-Severe Ulcerative Colitis in JapanPDF
March 12
Medicago, a subsidiary in Canada, is tackling with COVID-19, coronavirusPDF
February 26
Announcement Concerning Delisting of the Company SharesPDF
February 25
Change in Representative DirectorPDF
February 5
Mitsubishi Tanabe Pharma expands domestic co-promotion framework for STELARA. An application for an additional indication has been filed for ulcerative colitis, which will be included in co-promotion activities.PDF
February 4
Announcement of FY2019 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 17
Announcement of Mitsubishi Chemical Holdings Corporation’s Decision to Make a Demand for Sale of Our Shares, and Our Approval of that Demand for Sale of Our Shares and Delisting of Our SharesPDF
January 14
Change in Representative DirectorPDF
January 8
Announcement Concerning Results of the Tender Offer of Our Shares by Mitsubishi Chemical Holdings Corporation which is Our Controlling ShareholderPDF


November 27
Launch of Alesion LX Ophthalmic Solution 0.1% in JapanPDF
November 25
Mitsubishi Tanabe Pharma Announces the Start of a Phase 3 Clinical Trial using Oral Suspension of Edaravone for ALSPDF
November 18
Announcement of Mitsubishi Tanabe Pharma Corporation’s Opinion RegardingTender Offer for Shares in Mitsubishi Tanabe Pharma Corporation by the Controlling Shareholder Mitsubishi Chemical Holdings Corporation, and Recommendation to Tender SharesPDF
November 11
Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)PDF
November 11
HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019PDF
October 30
Announcement of FY2019 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
October 25
Revision to the First Half Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2020PDF
October 25
Vadadustat (MT-6548) Japan Phase 3 results for treatment of renal anemia to be presented at ASN Kidney Week 2019PDF
October 9
Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regionsPDF
October 2
Notification of acceptance of the New Drug Submission for Scientific Review of VLP Seasonal Influenza Vaccines(MT-2271)by Health CanadaPDF
September 30
Mitsubishi Tanabe Pharma to participate in new screening program through the Global Health Innovative Technology Fund ~Targeting treatments for infectious diseases that burden the developing countries~PDF
September 24
NMPA accepts our filing for TENELIA, a treatment agent for type 2 diabetes mellitus in ChinaPDF
September 20
Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion Ophthalmic Solution 0.05% and Alesion LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.PDF
September 17
Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatment agent edaravone in BrazilPDF
September 4
Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy productPDF
August 28
The Start of a Phase 3 Clinical Trial of Continuous Subcutaneous Liquid levodopa/carbidopa Administration (ND0612) for patients with fluctuating Parkinson’s diseasePDF
August 8
PhaseⅠClinical Trial study protocol for MT-3921 in Patients with Spinal Cord Injury submitted to the US INDPDF
August 8
Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia in Part of the ASEAN (Singapore and Thailand)PDF
August 7
NMPA approved Japan-originated ALS treatment Edaravone in ChinaPDF
August 6
Commencement of R&D of Gene Therapy Product for Hemophilia BPDF
July 29
Announcement of FY2019 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 23
Submission of Vadadustat (MT-6548) New Drug Application in Japan for renal anemiaPDF
May 30
Withdrawal of Marketing Authorization Application of edaravone for ALS in the European UnionPDF
May 29
Launch of SIMPONI Subcutaneous Injection 50mg AutoinjectorPDF
May 10
Announcement of Financial Results for FY2018
⇒R&D Pipeline "State of New Product Development"
April 26
Mitsubishi Tanabe Pharma and Salix enter into a licensing agreement for MT-1303, a therapeutic agent for autoimmune diseasesPDF
April 24
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019PDF
April 15
For the ALS patients in the world, we hope to deliver Japan-originated ALS treatment―NMPA accepts our filing for Radicut to treat ALS in ChinaPDF
April 11
Notice Regarding Reorganization of Research, Production, and Technology BasesPDF
March 28
The Global Health Innovative Technology Fund provides grant for joint research into anti-malarial drugs conducted by Mitsubishi Tanabe Pharma and a malaria research institutionPDF
March 26
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb IschemiaPDF
March 20
Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam Representative OfficePDF
March 12
Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia due to CKDPDF
February 28
Tianjin Tanabe and Servier Tianjin join hands to promote TENELIA in ChinaPDF
February 20
Mitsubishi Tanabe Pharma Received Notice of Request for ArbitrationPDF
February 14
FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid TumorsPDF
February 12
First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care AppPDF
February 6
Swissmedic approves RADICAVA, Japan-originated ALS treatmentPDF
February 4
Announcement of FY2018 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 4
Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.PDF

News Release

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide